Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1
Status:
Recruiting
Trial end date:
2026-07-31
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2, open label, multi-centre study to assess the safety, tolerability, PD,
and efficacy of adjuvant immunotherapy EVX-02 vaccine and anti-PD-1 (Nivolumab) in patients
who have had a complete resection of a Stage IIIB/IIIC/IIID or Stage IV melanoma who are at
high risk of recurrence.